On Thursday, Eli Lilly and Co. LLY said it will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom.The moves underscore growing competition with Danish rival Novo Nordisk A/S NVO in the lucrative obesity drug market.Starting in September, Lilly will raise the U.K. list price for Mounjaro’s highest monthly dose from 122 pounds to 330 pounds, a 170% jump, bringing it in line with prices in other European markets.Also Read: Eli Lilly Strikes ...